Edwards Lifesciences Reports Q3 2026 Growth Driven by Structural Heart Portfolio
Edwards Lifesciences (EW) reported strong third-quarter 2026 financial results, highlighted by total sales of $1.72 billion, representing an 11.2% increase on a constant currency basis. The growth was primarily fueled by the structural heart portfolio and rising global procedural volumes. Notably, Transcatheter Mitral and Tricuspid Therapies (TMTT) saw significant expansion with a 45.6% year-over-year sales increase. Following these results, the company raised its full-year sales guidance to approximately 11.5% growth. Management also increased FY 2026 TAVR and TMTT guidance, reflecting higher-than-expected procedural volumes and scaling U.S. adoption of new therapies. The company maintains a strong liquidity position with $3.1 billion in cash and continues its share repurchase program, having executed $700 million year-to-date.
Tickers: $EW
Topics: earnings report EPS guidance raise revenue growth TAVR sales
Read the full article at Motley Fool
Part of the story Holley Reports Q3 2026 Growth Driven by Core Business Acceleration and Portfolio Rebalancing (4 articles)